**Neurogenetic Therapies Programme**

**Expression of Interest form: Pre-clinical projects**

**Please return completed Expressions of Interest to:** [a.kiely@ucl.ac.uk](mailto:a.kiely@ucl.ac.uk) **by midday 18th May, maximum 3 pages**

|  |  |
| --- | --- |
| Expression of Interest form (3 pages maximum) | |
| Title of proposed project: |  |
| Contact details  Name:  Organisation:  Email: |  |
| Co-applicants: |  |
| Industrial partner:  Please provide details of any partner. Specify their involvement, role and contribution. Are they providing in-kind contributions, or direct funding? | |
|  | |
| Therapeutic target:  Please include a strong justification and mechanistic rationale | |
|  | |
| Disease and target patient population:  Include the rationale for selection of the particular disease. Is there a patient sub-population that can be targeted based upon e.g. genetics? Is there a particular stage of disease progression? | |
|  | |
| Therapeutic modality:  Please provide the reasoning for selection of the particular therapeutic modality | |
|  | |
| Description of project:  Please provide a clearly articulated plan for progression of the project, from eg idea through to in-vivo proof of concept. Smaller projects, which do not include progression all the way through to in-vivo studies in the first instance, are welcome. The use of relevant cellular models for selection of the optimised therapeutic should be described. The rationale for the selection and design of any animal studies (if included) must be clear, and the selected endpoints clearly described. Potential biomarkers of target engagement that have potential to be translated into the clinic should be included. The plan should include clear go/no-go decision points. | |
|  | |
| Budget:  Please provide costings (staff, travel, consumables, animals, equipment, etc) for the project proposal. Please also provide a brief justification. Also include any source of co-funding. | |
|  | |
| References  Key references (max 10): | |
|  | |